BIOLASE INC Stock Price, News & Analysis

BIOLASE has launched the Waterlase Fractional Handpiece in the U.S., enhancing skin resurfacing treatments with faster healing and recovery times. The handpiece is FDA 510(k) cleared and operates on the Waterlase iPlus platform, delivering both ablative and non-ablative treatments. Its proprietary water spray allows for procedures without anesthetics, improving patient comfort. BIOLASE targets the $215 million skin resurfacing market, aiming to increase the adoption of its technology in the dental industry. The handpiece has also shown success in international markets, providing effective solutions in cosmetic procedures.

BIOLASE, Inc. (NASDAQ: BIOL) has launched a new education web portal, Education.Biolase.com, enhancing its educational initiatives for dental professionals. The portal includes the Waterlase Academy and Epic Diode Academy, which provide tailored pathways for laser education. Offerings feature live seminars, classroom training, on-demand webinars, and extensive resources such as clinical video and animation libraries. BIOLASE aims to elevate dental care standards through this initiative, tapping into its 302 patented technologies designed to improve patient outcomes.

BIOLASE, a leader in dental lasers, will present at the Third Annual Winter Wonderland Best Ideas Virtual Investor Conference from February 21-24, 2023. The presentation is scheduled for February 21 at 2:00 p.m. PT (5:00 p.m. ET), with management hosting one-on-one meetings on February 23-24. This event is an opportunity for investors to learn more about BIOLASE's innovations in dental technology, comprising over 301 patents and 28 patent-pending technologies. For more information or to request an invitation, email angie.wright@issuerdirect.com. The presentation will be accessible via ir.biolase.com.

Strateos, a leader in lab automation and remote access labs, announced key management appointments aimed at enhancing growth and technology innovation. Alexander K. Arrow, MD, CFA, has been appointed Chief Financial Officer, while Juliet M. Moritz, MPH, will serve as Vice President of the Project Management Office. Arrow's extensive experience in finance and medical technology will guide the company's financial strategy, while Moritz will oversee the deployment of the Lodestar Software, crucial for drug discovery processes. These appointments come in response to increasing demand from pharmaceutical firms for Strateos' innovative services.

On January 25, 2023, BIOLASE, Inc. (NASDAQ: BIOL) publicly responded to Sonendo, Inc.'s patent litigation, deeming the claims 'meritless' and an attempt to undermine BIOLASE's market position. BIOLASE, known for its dental laser innovations, asserts that Sonendo's claims overlap with conventional technologies and lack true innovation. The company's CEO, John Beaver, criticized Sonendo's product quality and referred to an FDA Class 2 device recall concerning Sonendo's GentleWave system. BIOLASE plans to vigorously defend against the claims and emphasizes its position in the market, aiming to expand its share with superior products and robust intellectual property.

On January 25, 2023, BIOLASE (NASDAQ: BIOL) responded to Sonendo's legal claims regarding patent infringement. BIOLASE regards these claims as meritless and intends to challenge them vigorously, asserting that they overlap with existing technologies. John Beaver, CEO of BIOLASE, criticized Sonendo's products as inferior and costly, referencing a recent FDA recall on its GentleWave system. BIOLASE emphasizes its commitment to maintaining market leadership through innovative laser technology and a robust intellectual property portfolio, with over 302 patents and extensive global sales.

BIOLASE, Inc., a leader in dental lasers, announced that preliminary revenue for Q4 2022 is expected between $14.0 million and $14.4 million, representing a 13% to 16% increase from Q4 2021. Full-year 2022 revenue is anticipated to reach $48.4 million to $48.8 million, a growth of 24% to 25% compared to the previous year. The company highlights strong adoption of its Waterlase products, with 84% of sales coming from new customers. Looking ahead, BIOLASE aims for at least 25% revenue growth in 2023, positive adjusted EBITDA, and further market penetration through various initiatives.